Marina Konopleva

70.2k total citations · 6 hit papers
917 papers, 30.5k citations indexed

About

Marina Konopleva is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Marina Konopleva has authored 917 papers receiving a total of 30.5k indexed citations (citations by other indexed papers that have themselves been cited), including 610 papers in Hematology, 377 papers in Molecular Biology and 247 papers in Genetics. Recurrent topics in Marina Konopleva's work include Acute Myeloid Leukemia Research (478 papers), Chronic Myeloid Leukemia Treatments (210 papers) and Acute Lymphoblastic Leukemia research (182 papers). Marina Konopleva is often cited by papers focused on Acute Myeloid Leukemia Research (478 papers), Chronic Myeloid Leukemia Treatments (210 papers) and Acute Lymphoblastic Leukemia research (182 papers). Marina Konopleva collaborates with scholars based in United States, Japan and Canada. Marina Konopleva's co-authors include Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi, Courtney D. DiNardo, Jörge E. Cortes, Gautam Borthakur, Tapan M. Kadia, Naval Daver, Guillermo Garcia‐Manero and Elias Jabbour and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Marina Konopleva

878 papers receiving 30.1k citations

Hit Papers

Venetoclax combined with ... 2009 2026 2014 2020 2018 2009 2018 2021 2020 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
    2018 1.2k citations Courtney D. DiNardo, Marina Konopleva et al. Blood profile →
  2. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
    2009 552 citations Ismael Samudio, Hagop M. Kantarjian et al. Journal of Clinical Investigation profile →
  3. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
    2018 498 citations Courtney D. DiNardo, Hagop M. Kantarjian et al. The Lancet Oncology profile →
  4. Acute myeloid leukemia: current progress and future directions
    2021 471 citations Hagop M. Kantarjian, Tapan M. Kadia et al. profile →
  5. MDM2 inhibition: an important step forward in cancer therapy
    2020 276 citations Marina Konopleva, Naval Daver et al. profile →
  6. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
    2020 243 citations Nicholas J. Short, Marina Konopleva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marina Konopleva United States 94 15.8k 15.6k 7.9k 5.9k 4.3k 917 30.5k
Elihu H. Estey United States 100 16.0k 1.0× 27.6k 1.8× 8.6k 1.1× 8.7k 1.5× 8.7k 2.0× 687 39.7k
Bob Löwenberg Netherlands 89 14.3k 0.9× 23.5k 1.5× 8.0k 1.0× 5.9k 1.0× 6.5k 1.5× 534 35.9k
Farhad Ravandi United States 90 13.0k 0.8× 24.8k 1.6× 7.5k 0.9× 10.4k 1.8× 9.3k 2.2× 1.3k 34.7k
Zeev Estrov United States 82 11.7k 0.7× 13.3k 0.9× 4.8k 0.6× 10.5k 1.8× 3.1k 0.7× 669 26.3k
Michael Andreeff United States 112 25.9k 1.6× 16.0k 1.0× 13.6k 1.7× 10.3k 1.8× 4.2k 1.0× 1.0k 48.1k
Alan F. List United States 68 8.3k 0.5× 15.4k 1.0× 4.2k 0.5× 6.5k 1.1× 2.5k 0.6× 621 21.9k
Guillermo Garcia‐Manero United States 106 17.8k 1.1× 30.6k 2.0× 7.5k 0.9× 14.7k 2.5× 8.3k 1.9× 1.5k 44.1k
Kapil N. Bhalla United States 87 17.3k 1.1× 6.5k 0.4× 5.9k 0.7× 3.7k 0.6× 1.2k 0.3× 378 26.0k
Guido Marcucci United States 77 14.3k 0.9× 9.8k 0.6× 3.1k 0.4× 3.2k 0.5× 2.7k 0.6× 489 22.5k
Maher Albitar United States 65 7.5k 0.5× 9.2k 0.6× 4.5k 0.6× 8.2k 1.4× 1.8k 0.4× 342 20.0k

Countries citing papers authored by Marina Konopleva

Since Specialization
Citations

This map shows the geographic impact of Marina Konopleva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Konopleva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Konopleva more than expected).

Fields of papers citing papers by Marina Konopleva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Konopleva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Konopleva. The network helps show where Marina Konopleva may publish in the future.

Co-authorship network of co-authors of Marina Konopleva

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Konopleva. A scholar is included among the top collaborators of Marina Konopleva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Konopleva. Marina Konopleva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Konopleva, Marina, et al.. (2024). Novel Therapeutic Targets in Acute Myeloid Leukemia (AML). Current Oncology Reports. 26(4). 409–420. 17 indexed citations
3.
Daver, Naval, Pau Montesinos, Daniel J. DeAngelo, et al.. (2024). Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. The Lancet Oncology. 25(3). 388–399. 34 indexed citations
4.
Yennurajalingam, Sriram, Marina Konopleva, Cindy L. Carmack, et al.. (2022). Treatment of Cancer-related-Fatigue in Acute Hematological Malignancies: Results of a Feasibility Study of using Cognitive Behavioral Therapy. Journal of Pain and Symptom Management. 65(3). e189–e197. 6 indexed citations
5.
Bazinet, Alexandre, Tapan M. Kadia, Sangeetha Venugopal, et al.. (2022). A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 129(4). 560–568. 6 indexed citations
6.
Chifotides, Helen T., Lucia Masárová, Mansour Alfayez, et al.. (2020). Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Advances. 4(21). 5336–5342. 37 indexed citations
7.
Kannan, Sankaranarayanan, Shelley M. Herbrich, Leonard S. Golfman, et al.. (2019). Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 18(9). 1615–1627. 9 indexed citations
8.
Piya, Sujan, Hong Mu, Seemana Bhattacharya, et al.. (2019). BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment. Journal of Clinical Investigation. 129(5). 1878–1894. 56 indexed citations
9.
Chan, Wai-Kin, Thomas D. Horvath, Lin Tan, et al.. (2019). Glutaminase Activity of L -Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 18(9). 1587–1592. 60 indexed citations
10.
Zacharias, Niki M., Natalia Baran, Sriram S. Shanmugavelandy, et al.. (2019). Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 18(11). 1937–1946. 22 indexed citations
11.
Pemmaraju, Naveen, Hagop M. Kantarjian, Joseph D. Khoury, et al.. (2017). Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 130. 3855–3855. 5 indexed citations
12.
Rausch, Caitlin R., Courtney D. DiNardo, Tapan M. Kadia, et al.. (2017). Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies. Blood. 130. 1356–1356. 3 indexed citations
13.
Nguyen, Duc, William Pandori, Sharmila Mallya, et al.. (2017). mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Molecular Cancer Therapeutics. 16(9). 1942–1953. 11 indexed citations
14.
Zhang, Weiguo, Gautam Borthakur, Gao Chen, et al.. (2016). The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Cancer Research. 76(6). 1528–1537. 52 indexed citations
15.
Pan, Rongqing, Vivian Ruvolo, Jun Wei, et al.. (2015). Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 126(3). 363–372. 111 indexed citations
16.
Konopleva, Marina, Roland B. Walter, Stefan Faderl, et al.. (2014). Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clinical Cancer Research. 20(8). 2226–2235. 70 indexed citations
17.
Zhang, Weiguo, Vivian Ruvolo, Gao Chen, et al.. (2014). Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(7). 1848–1859. 30 indexed citations
18.
Pierceall, William E., Steven M. Kornblau, Nicole E. Carlson, et al.. (2013). BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia. Molecular Cancer Therapeutics. 12(12). 2940–2949. 22 indexed citations
19.
20.
Konopleva, Marina, Rooha Contractor, Peter P. Ruvolo, et al.. (2006). Mechanism of apoptosis induction by chemical inhibitors of bcl-2 in acute leukemia cells. Cancer Research. 66. 1142–1143. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elihu H. Estey Breakdown of academic impact, for papers by Bob Löwenberg Breakdown of academic impact, for papers by Farhad Ravandi Breakdown of academic impact, for papers by Zeev Estrov Breakdown of academic impact, for papers by Michael Andreeff Breakdown of academic impact, for papers by Alan F. List Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Kapil N. Bhalla Breakdown of academic impact, for papers by Guido Marcucci Breakdown of academic impact, for papers by Maher Albitar
Rankless by CCL
2026